Sangart
closedBiopharmaceutical company developing global scientific, clinical and commercial oxygen-therapeutic agents.
Launch date
Employees
Market cap
-
Enterprise valuation
CAD273—409m (Dealroom.co estimates May 2012.)
San Diego California (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | $1.5m | Series C | |
| N/A | $852k | Debt | |
$12.0m | Debt | ||
| N/A | $15.0m | Series E | |
$50.0m | Series F | ||
$100m | Series F | ||
| N/A | $15.1m | Debt | |
$50.0m | Early VC | ||
$50.0m | Series G | ||
| Total Funding | CAD363m | ||
Recent News about Sangart
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.